Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06617286 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Dec 1, 2024 to Dec 1, 2026v3
  2. Primary completion date: Dec 31, 2040 to Dec 31, 2039v2 Show 6 more changesShow less
    • Primary endpoints: 1 to 2
    • Enrollment target: 27 to 21
    • Study completion date: Dec 31, 2041 to Dec 31, 2040
    • Start date: Jun 1, 2025 to Dec 1, 2024
    • Study description expanded, about 8 words
    • Eligibility criteria shortened, about 1 word
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Trial Details
NCT Number NCT06617286
Lead Sponsor New York Medical College
Collaborators: University of North Carolina
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov